IDXX · 8-K · 20260804PR090033
Capital Expenditures and Cash Flow
IDEXX LABORATORIES INC /DE · 2026-08-04 · Importance 85 · Surprise 64 · No source text
Six-month cash flow from operations increased 45% to $613.4 million from $423.7 million. Six-month free cash flow increased 55% to $556.8 million from $359.6 million after $56.6 million of property and equipment purchases. Second-quarter free cash flow was $322.5 million, up from $151.6 million. Full-year 2026 capital expenditures are projected at approximately $180 million, with free-cash-flow conversion projected at 90%-100% of net income.
Key facts
- Company projects full year 2026 capital expenditures of approximately $180 million. source
- Net cash provided by operating activities for six months ended June 30, 2026: $613,410 compared to $423,705 in 2025. source
- Free cash flow for six months ended June 30, 2026: $556,780 compared to $359,577 for six months ended June 30, 2025. source
- Free cash flow (% of net income) projected for 2026: 90% - 100% versus prior 85% - 95%. source
- Purchases of property and equipment for six months ended June 30, 2026: $56,630; for six months ended June 30, 2025: $64,128. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | committed | — | Company projects full year 2026 capital expenditures of approximately $180 million. |
| assets | positive | committed | — | Company projects full year 2026 capital expenditures of approximately $180 million. |
| cash | positive | realized | — | Net cash provided by operating activities for six months ended June 30, 2026: $613,410 compared to $423,705 in 2025. |
| cash | positive | realized | — | Free cash flow for six months ended June 30, 2026: $556,780 compared to $359,577 for six months ended June 30, 2025. |
| cash | positive | committed | — | Free cash flow (% of net income) projected for 2026: 90% - 100% versus prior 85% - 95%. |